Cypher class action suit?
This article was originally published in The Gray Sheet
Executive Summary
Kenneth B. Moll & Associates will decide by year-end whether to pursue a class action suit against Johnson & Johnson/Cordis for deaths related to implantation of its sirolimus-eluting stent. Moll currently is conducting an investigation of Cypher patient data FDA released in October that estimated a 0.01% worldwide mortality rate for the device (1"The Gray Sheet" Nov. 3, 2003, p. 4). In June, the Chicago law firm brought a class action suit against Guidant because of deaths related to its Ancure AAA system; the suit is currently in discovery...
You may also be interested in...
Thrombosis Events May Be Clarified By e-CYPHER Data Expected In February
FDA's public health notification related to adverse events for J&J/Cordis' Cypher is intended to generate further data collection for the drug-eluting stent rather than raise undue concern over clotting issues, the agency says
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.